In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.
Nicholas C. Turner, MD
Advertisement
Articles by Nicholas C. Turner, MD
Advertisement
Latest Updated Articles
Adding Palbociclib Delays Progression in HR-Positive Breast CancerPublished: June 2nd 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
4
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
5
